Published Paper Details:

By the age of 50, approximatelyone-half of all males and females get androgenic alopecia (AGA), a condition characterized by progressive hair loss on the scalp, impacting self-esteem and physical appearance. AGA is attributed to the increased activity of 5-reductase enzyme in scalp hair follicles, leading to conversion of testosterone to dihydrotestosterone (DHT). Finasteride, a synthetic 4-aza-3-oxosteroid with low water solubility, inhibits this conversion, resulting in reduced DHT levels and hair loss mitigation.Although minoxidil, potassium channel opener and vasodilator, promotes hair growth by enhancing blood flow and nutrient delivery to the scalp,its precise mechanism for stimulating hair growth remains ambiguous and seems to operate separately from its vasodilatory effects. The investigations on both medications found that combining minoxidil and finasteride had a superior effect on hair loss than either therapy alone. Combining finasteride and minoxidil has shown superior efficacy compared to either drug alone in treating hair loss. To address limitations of current formulations, a topical preparation combining finasteride and minoxidil is needed, optimizing drug-to-scalp contact, reducing administration frequency, enhancing penetration, stimulating hair follicles, and improving hair growth. Utilizing niosomes, which act as localized drug depots, could prolong drug release and improve therapeutic outcomes while minimizing systemic adverse effects of finasteride.